DFTX earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E -17.47. Updated 2026-07-23.
Definium Therapeutics (DFTX) Research Hub
Definium Therapeutics (DFTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 38.89 USD (+2.37%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -17.47, market cap 4.77B. This hub links to the full technical, earnings and options research available for DFTX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 38.89 USD (+2.37%) |
| 52-week range | 23.63 USD – 49.7 USD |
| Trend regime | Range |
| 14-day RSI | 31.2 (Bearish) |
| Trailing P/E | -17.47 |
| Market cap | 4.77B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for DFTX
Covered Call on DFTX: how it works, illustrative setup around the real 38.89 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DFTX: how it works, illustrative setup around the real 38.89 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DFTX: how it works, illustrative setup around the real 38.89 USD price, max profit/loss, breakeven and when to use it. Educational.
DFTX technical analysis: range, last 38.89 USD, RSI 31.2, 52w range 23.63 USD–49.7 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is DFTX in?
Definium Therapeutics (DFTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is DFTX in an uptrend or downtrend?
As of 2026-09-11, DFTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DFTX's trailing P/E ratio?
DFTX's trailing P/E is -17.47, with a market cap of 4.77B. See the earnings research page for full valuation detail.
When does DFTX next report earnings?
DFTX is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of -0.55 USD.